NO331974B1 - Fremgangsmate for a detektere i en biologisk prove et kompleks av chaperon Q2 og beta-amyloid, antistoff som gjenkjenner komplekset og anvendelse av chaperon Q2 for fremstilling av et preparat for behandling av Alzheimers sykdom. - Google Patents

Fremgangsmate for a detektere i en biologisk prove et kompleks av chaperon Q2 og beta-amyloid, antistoff som gjenkjenner komplekset og anvendelse av chaperon Q2 for fremstilling av et preparat for behandling av Alzheimers sykdom. Download PDF

Info

Publication number: NO331974B1
Authority: NO; Norway
Prior art keywords: amyloid; chaperone; complex; disease; level
Prior art date: 1998-10-30

Application number

NO20012114A

Other languages

English (en)

Norwegian (no)

Other versions

NO20012114D0 (no

NO20012114L (no

Inventor

Jordan Holtzman

Original Assignee

Jordan Holtzman

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-30

Filing date

2001-04-27

Publication date

2012-05-14

2001-04-27 Application filed by Jordan Holtzman filed Critical Jordan Holtzman

2001-04-27 Publication of NO20012114D0 publication Critical patent/NO20012114D0/no

2001-06-14 Publication of NO20012114L publication Critical patent/NO20012114L/no

2012-05-14 Publication of NO331974B1 publication Critical patent/NO331974B1/no

Links

108010090849 Amyloid beta-Peptides Proteins 0.000 title claims abstract description 113
102000013455 Amyloid beta-Peptides Human genes 0.000 title claims abstract description 113
108010006519 Molecular Chaperones Proteins 0.000 title claims abstract description 105
238000000034 method Methods 0.000 title claims abstract description 93
208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 69
239000012472 biological sample Substances 0.000 title claims abstract description 40
238000011282 treatment Methods 0.000 title claims description 4
239000000203 mixture Substances 0.000 title description 4
230000007423 decrease Effects 0.000 claims abstract description 50
208000000340 Alzheimer disease type 1 Diseases 0.000 claims abstract description 19
238000012216 screening Methods 0.000 claims abstract description 11
230000006933 amyloid-beta aggregation Effects 0.000 claims abstract description 5
210000001175 cerebrospinal fluid Anatomy 0.000 claims description 54
241001465754 Metazoa Species 0.000 claims description 46
208000037259 Amyloid Plaque Diseases 0.000 claims description 25
230000015572 biosynthetic process Effects 0.000 claims description 21
230000002776 aggregation Effects 0.000 claims description 17
238000004220 aggregation Methods 0.000 claims description 17
210000003169 central nervous system Anatomy 0.000 claims description 13
239000012620 biological material Substances 0.000 claims description 10
239000000463 material Substances 0.000 claims description 10
238000003018 immunoassay Methods 0.000 claims description 9
101150037123 APOE gene Proteins 0.000 claims description 7
101100216294 Danio rerio apoeb gene Proteins 0.000 claims description 7
238000001514 detection method Methods 0.000 claims description 5
238000002875 fluorescence polarization Methods 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
230000008859 change Effects 0.000 claims description 3
230000003542 behavioural effect Effects 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
102000005431 Molecular Chaperones Human genes 0.000 abstract description 43
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 21
201000010099 disease Diseases 0.000 abstract description 20
208000024891 symptom Diseases 0.000 abstract description 9
102100029470 Apolipoprotein E Human genes 0.000 abstract description 3
101710095339 Apolipoprotein E Proteins 0.000 abstract description 3
241000124008 Mammalia Species 0.000 abstract description 3
239000012530 fluid Substances 0.000 abstract description 3
108090000623 proteins and genes Proteins 0.000 description 47
235000018102 proteins Nutrition 0.000 description 43
102000004169 proteins and genes Human genes 0.000 description 43
241000700159 Rattus Species 0.000 description 26
108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 25
238000003119 immunoblot Methods 0.000 description 25
230000006870 function Effects 0.000 description 20
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 19
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 19
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 18
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 18
230000003228 microsomal effect Effects 0.000 description 14
230000002440 hepatic effect Effects 0.000 description 13
102000034342 Calnexin Human genes 0.000 description 11
108010056891 Calnexin Proteins 0.000 description 11
230000000875 corresponding effect Effects 0.000 description 11
239000012528 membrane Substances 0.000 description 11
210000001589 microsome Anatomy 0.000 description 11
108090000549 Calreticulin Proteins 0.000 description 10
102000004082 Calreticulin Human genes 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
230000003938 response to stress Effects 0.000 description 9
210000004027 cell Anatomy 0.000 description 8
210000004185 liver Anatomy 0.000 description 8
238000012545 processing Methods 0.000 description 8
230000009467 reduction Effects 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
102100037089 Protein disulfide-isomerase A4 Human genes 0.000 description 7
238000001042 affinity chromatography Methods 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
230000000694 effects Effects 0.000 description 7
108010063267 endoplasmic reticulum glycoprotein p72 Proteins 0.000 description 7
108700028369 Alleles Proteins 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
241000287828 Gallus gallus Species 0.000 description 5
230000032683 aging Effects 0.000 description 5
235000013330 chicken meat Nutrition 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
239000002243 precursor Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
108091058545 Secretory proteins Proteins 0.000 description 4
102000040739 Secretory proteins Human genes 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
150000001720 carbohydrates Chemical group 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
230000001932 seasonal effect Effects 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
239000013598 vector Substances 0.000 description 4
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
241000283707 Capra Species 0.000 description 3
108010004889 Heat-Shock Proteins Proteins 0.000 description 3
102000002812 Heat-Shock Proteins Human genes 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
241000276498 Pollachius virens Species 0.000 description 3
102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000008021 deposition Effects 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000037213 diet Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940012952 fibrinogen Drugs 0.000 description 3
238000002955 isolation Methods 0.000 description 3
230000035882 stress Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 2
230000007351 Aβ plaque formation Effects 0.000 description 2
208000014644 Brain disease Diseases 0.000 description 2
101710106383 Disulfide bond formation protein B Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
241000282412 Homo Species 0.000 description 2
108091006036 N-glycosylated proteins Proteins 0.000 description 2
230000004988 N-glycosylation Effects 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
101710116318 Probable disulfide formation protein Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
101710106224 Protein disulfide-isomerase A3 Proteins 0.000 description 2
239000012506 Sephacryl® Substances 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
-1 TPDO-Q2 Proteins 0.000 description 2
238000011888 autopsy Methods 0.000 description 2
210000004958 brain cell Anatomy 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
230000003915 cell function Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000001378 electrochemiluminescence detection Methods 0.000 description 2
210000002472 endoplasmic reticulum Anatomy 0.000 description 2
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
210000001723 extracellular space Anatomy 0.000 description 2
239000012634 fragment Substances 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000009593 lumbar puncture Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
230000006911 nucleation Effects 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000012846 protein folding Effects 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
230000033764 rhythmic process Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108010060159 Apolipoprotein E4 Proteins 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
102000052603 Chaperonins Human genes 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
101001098802 Homo sapiens Protein disulfide-isomerase A3 Proteins 0.000 description 1
101001098824 Homo sapiens Protein disulfide-isomerase A4 Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003198 anti-chaperone Effects 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
125000005621 boronate group Chemical group 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000003936 denaturing gel electrophoresis Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000020931 dietary conditions Nutrition 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
230000008717 functional decline Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000003862 health status Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000006101 laboratory sample Substances 0.000 description 1
230000000503 lectinlike effect Effects 0.000 description 1
239000002906 medical waste Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000013188 needle biopsy Methods 0.000 description 1
210000000478 neocortex Anatomy 0.000 description 1
210000002682 neurofibrillary tangle Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007171 neuropathology Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
210000001152 parietal lobe Anatomy 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
238000012510 peptide mapping method Methods 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
229960002635 potassium citrate Drugs 0.000 description 1
239000001508 potassium citrate Substances 0.000 description 1
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
235000011082 potassium citrates Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000003161 proteinsynthetic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000012521 purified sample Substances 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000007790 scraping Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000002693 spinal anesthesia Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
210000003411 telomere Anatomy 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
210000003478 temporal lobe Anatomy 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Pharmacology & Pharmacy (AREA)
Hospice & Palliative Care (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20012114A 1998-10-30 2001-04-27 Fremgangsmate for a detektere i en biologisk prove et kompleks av chaperon Q2 og beta-amyloid, antistoff som gjenkjenner komplekset og anvendelse av chaperon Q2 for fremstilling av et preparat for behandling av Alzheimers sykdom. NO331974B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10639898P	1998-10-30	1998-10-30
US12356499P	1999-03-10	1999-03-10
PCT/US1999/025593 WO2000026251A2 (en)	1998-10-30	1999-10-29	A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX

Publications (3)

Publication Number	Publication Date
NO20012114D0 NO20012114D0 (no)	2001-04-27
NO20012114L NO20012114L (no)	2001-06-14
NO331974B1 true NO331974B1 (no)	2012-05-14

Family

ID=26803625

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20012114A NO331974B1 (no)	1998-10-30	2001-04-27	Fremgangsmate for a detektere i en biologisk prove et kompleks av chaperon Q2 og beta-amyloid, antistoff som gjenkjenner komplekset og anvendelse av chaperon Q2 for fremstilling av et preparat for behandling av Alzheimers sykdom.

Country Status (12)

Country	Link
US (3)	US6972318B1 (de)
EP (1)	EP1125135B1 (de)
JP (1)	JP4571310B2 (de)
AT (1)	ATE284538T1 (de)
AU (1)	AU764713B2 (de)
CA (1)	CA2348545C (de)
DE (1)	DE69922535T2 (de)
IL (2)	IL142852A0 (de)
MX (1)	MXPA01004317A (de)
NO (1)	NO331974B1 (de)
NZ (1)	NZ511589A (de)
WO (1)	WO2000026251A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ522951A (en) *	2000-05-24	2004-11-26	Jordan Loyal Holtzman	Biphenylmethane compounds as agents for increasing brain chaperonin levels
US6962982B2 (en)	2001-06-22	2005-11-08	Roche Diagnostics Corporation	Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
US7094884B2 (en)	2001-06-22	2006-08-22	Roche Diagnostics Corporation	Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
US7094757B2 (en)	2001-06-22	2006-08-22	Roche Diagnostics Corporation	Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
ES2294196T3 (es) *	2002-12-20	2008-04-01	F. Hoffmann-La Roche Ag	Metodos para elaborar y utilizar complejos solubles de proteinas diana y chaperonas peptil prolil isomerasas.
US9335331B2 (en) *	2005-04-11	2016-05-10	Cornell Research Foundation, Inc.	Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
JP4981305B2 (ja) *	2005-11-11	2012-07-18	公益財団法人大阪バイオサイエンス研究所	アルツハイマー病の発症リスク又はアルツハイマー病発症予後の予測方法
TW201214809A (en) *	2010-01-29	2012-04-01	Nitto Denko Corp	Light-emitting diode device
EP2694977B1 (de) *	2011-04-05	2016-06-29	Alphabeta AB	Amyloidose-target zum screening von verbindungen
WO2012142301A2 (en)	2011-04-12	2012-10-18	Quanterix Corporation	Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
CA2879103A1 (en) *	2012-07-13	2014-01-16	Jordan L. Holtzman	Cellular and animal models for screening therapeutic agents for the treatment of alzheimer's disease
US20180099024A1 (en) *	2016-10-06	2018-04-12	Ramp Research, Llc	Methods, compositions, and kits involving alteration of the chaperone protein axis in a subject

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5223482A (en) *	1986-11-17	1993-06-29	Scios Nova Inc.	Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5780587A (en)	1990-08-24	1998-07-14	President And Fellows Of Harvard College	Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
EP0683234B2 (de) *	1993-01-25	2007-06-06	Takeda Chemical Industries, Ltd.	Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5707821A (en) *	1995-06-07	1998-01-13	Athena Neurosciences, Inc.	Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease
JPH09178743A (ja)	1995-12-27	1997-07-11	Oriental Yeast Co Ltd	可溶性ａｐｐの定量法
NZ524395A (en)	1997-12-10	2004-10-29	Nps Pharma Inc	Anticonvulsant and central nervous system-active bis(fluorophenyl) alkylamides

1999
- 1999-10-29 AT AT99961552T patent/ATE284538T1/de not_active IP Right Cessation
- 1999-10-29 JP JP2000579637A patent/JP4571310B2/ja not_active Expired - Fee Related
- 1999-10-29 DE DE69922535T patent/DE69922535T2/de not_active Expired - Lifetime
- 1999-10-29 AU AU18105/00A patent/AU764713B2/en not_active Ceased
- 1999-10-29 EP EP99961552A patent/EP1125135B1/de not_active Expired - Lifetime
- 1999-10-29 NZ NZ511589A patent/NZ511589A/en not_active IP Right Cessation
- 1999-10-29 MX MXPA01004317A patent/MXPA01004317A/es active IP Right Grant
- 1999-10-29 CA CA2348545A patent/CA2348545C/en not_active Expired - Fee Related
- 1999-10-29 IL IL14285299A patent/IL142852A0/xx unknown
- 1999-10-29 US US09/830,749 patent/US6972318B1/en not_active Expired - Lifetime
- 1999-10-29 WO PCT/US1999/025593 patent/WO2000026251A2/en not_active Ceased
2001
- 2001-04-27 NO NO20012114A patent/NO331974B1/no not_active IP Right Cessation
- 2001-04-29 IL IL142852A patent/IL142852A/en not_active IP Right Cessation
2005
- 2005-09-19 US US11/231,065 patent/US7927824B2/en not_active Expired - Fee Related
2011
- 2011-04-19 US US13/089,940 patent/US8211658B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7927824B2 (en)	2011-04-19
NO20012114D0 (no)	2001-04-27
US8211658B2 (en)	2012-07-03
DE69922535D1 (de)	2005-01-13
DE69922535T2 (de)	2005-05-12
US6972318B1 (en)	2005-12-06
ATE284538T1 (de)	2004-12-15
US20110256569A1 (en)	2011-10-20
MXPA01004317A (es)	2003-06-06
AU1810500A (en)	2000-05-22
JP2002528555A (ja)	2002-09-03
NZ511589A (en)	2005-02-25
AU764713B2 (en)	2003-08-28
NO20012114L (no)	2001-06-14
CA2348545A1 (en)	2000-05-11
US20060024759A1 (en)	2006-02-02
IL142852A (en)	2010-05-31
WO2000026251A2 (en)	2000-05-11
WO2000026251A9 (en)	2001-01-04
WO2000026251A3 (en)	2000-08-10
IL142852A0 (en)	2002-03-10
JP4571310B2 (ja)	2010-10-27
CA2348545C (en)	2012-08-21
EP1125135A2 (de)	2001-08-22
EP1125135B1 (de)	2004-12-08

Legal Events

Date

Code

Title

Description

2007-10-15

ERR

Erratum

Free format text: I PATENTTIDENDE NR. 22/07 BLE PATENTSOKNAD NR. 20012114 FEILAKTIG KUNNGJORT ENDELIG HENLAGT. SOKNADEN ER FORTSATT UNDER BEHANDLING

Free format text: I PATENTTIDENDE NR. 22/07 BLE PATENTSOKNAD NR. 20012114 FEILAKTIG KUNNGJORT ENDELIG HENLAGT. SOKNADEN ER FORTSATT UNDER BEHANDLING.

2015-05-26

MM1K

Lapsed by not paying the annual fees

Publication	Publication Date	Title
US8211658B2 (en)	2012-07-03	Complex of a chaperone with β-amyloid and methods employing this complex
Charkoftaki et al.	2019	Update on the human and mouse lipocalin (LCN) gene family, including evidence the mouse Mup cluster is result of an “evolutionary bloom”
Cline et al.	2018	The amyloid-β oligomer hypothesis: beginning of the third decade
Kisilevsky et al.	1997	AßT Amyloidogenesis: Unique, or Variation on a Systemic Theme
St George-Hyslop	1999	Molecular genetics of Alzheimer disease
Juul Rasmussen et al.	2023	Modifiable cardiovascular risk factors and genetics for targeted prevention of dementia
Gibson et al.	1996	Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients
Lannfelt et al.	1995	Amyloid β-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation
へ下へ et al.	2005	An overview of Alzheimer's disease
Lace et al.	2007	A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases
Bornebroek et al.	1999	Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): a review of the variety in phenotypic expression
Ortiz et al.	2015	Genetic, Biochemical and Histopathological Aspects of
Frisardi	2012	Apolipoprotein E genotype: the innocent bystander or active bridge between metabolic syndrome and cognitive impairment?
Crabbe et al.	2001	Small heat shock proteins (sHSPs) as potential drug targets
Cervia et al.	2006	An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease
Maiese	2008	Neurovascular Medicine Pursuing Cellular Longevity for Healthy Aging
Huynh	2020	The Role of Apolipoprotein E in Alzheimer Disease: From Therapy to Mechanism
Li	2016	The pathogenesis of soluble PrP fragments containing Aβ binding sites
Perez et al.	2022	Down Syndrome, Neurodegeneration and Dementia
Amaducci et al.	1994	Risk factors for dementia
Evans	1996	Conformational studies of the beta amyloid protein and in vitro models for the effects of apolipoprotein E on fibril formation in Alzheimer's disease
Malcolm	2019	Elucidating tau-mediated neurodegeneration, inflammation and vasculopathy: insights into tauopathies gained by a novel transgenic rat model
Gary	2016	Experimental Transmission of Alzheimer's Disease Endophenotypes to Murine and Primate Models
LaClair	2016	DEPLETION OF TDP-43 ACCELERATES NEURODEGENERATION IN AN ALZHEIMER’S MOUSE MODEL, INDEPENDENT OF BETA-AMYLOID PLAQUE BURDEN
Mukaetova-Ladinska et al.	1995	Alzheimer's disease—new approaches to old problems